Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12184676 | 0.86 | SLC6A4 (0.64) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL6496199 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL26049997 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL11466711 | 0.82 | DRD2 (0.53) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL15649004 | 0.82 | HRH3 (0.53) | CHRNB2CHRNA4ROCK1ROCK2PRKX | |
| SCHEMBL940415 | 0.82 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL1409317 | 0.81 | SLC6A2 (0.69) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL69675 | 0.81 | SLC6A2 (0.65) | SLC6A2SLC6A3SLC6A4DRD2DRD3 | |
| SCHEMBL14017656 | 0.81 | CHRNB2 (0.58) | SLC6A2CHRNB2CHRNA4ROCK1ROCK2 | |
| SCHEMBL23745914 | 0.79 | CHRNB2 (0.57) | SLC6A2SLC6A3SLC6A4CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| WO-2014060341-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SLC6A2 218/4885SLC6A3 248/4885SLC6A4 207/4885 |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | SLC6A2 1771/4885SLC6A3 795/4885SLC6A4 948/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SLC6A2 218/4885SLC6A3 248/4885SLC6A4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.